Zobrazeno 1 - 10
of 500
pro vyhledávání: '"Edward S Kim"'
Publikováno v:
PLoS ONE, Vol 11, Iss 1, p e0147234 (2016)
Modified nucleosides have the potential to inhibit DNA polymerases for the treatment of viral infections and cancer. With the hope of developing potent drug candidates by the modification of the 2',4'-position of the ribose with the inclusion of a br
Externí odkaz:
https://doaj.org/article/8adbc535efcd4ca28cfe5f04a54c4359
Autor:
Megan H. Jagosky, Colin J. Anderson, James T. Symanowski, Nury M. Steuerwald, Carol J. Farhangfar, Emily A. Baldrige, Jennifer H. Benbow, Michael B. Livingston, Joshua C. Patt, Will A. Ahrens, Jeffrey S. Kneisl, Edward S. Kim
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 7029-7038 (2023)
Abstract Purpose Patients with unresectable dedifferentiated liposarcoma (DDLPS) have poor overall outcomes. Few genomic alterations have been identified with limited therapeutic options. Experimental Design Patients treated at Levine Cancer Institut
Externí odkaz:
https://doaj.org/article/7e061913e58d4d3093d3ab4b289a48b5
Autor:
Scott N. Gettinger, MD, Rudolf M. Huber, MD, PhD, Dong-Wan Kim, MD, PhD, Lyudmila Bazhenova, MD, Karin Holmskov Hansen, MD, Marcello Tiseo, MD, Corey J. Langer, MD, FACP, Luis G. Paz-Ares Rodríguez, MD, PhD, Howard L. West, MD, Karen L. Reckamp, MD, MS, Glen J. Weiss, MD, Egbert F. Smit, MD, PhD, Maximilian J. Hochmair, MD, Sang-We Kim, MD, PhD, Myung-Ju Ahn, MD, PhD, Edward S. Kim, MD, FACP, Harry J.M. Groen, MD, PhD, Joanna Pye, MS, Yuyin Liu, PhD, Pingkuan Zhang, MD, Florin Vranceanu, MD, PhD, D. Ross Camidge, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100385- (2022)
Introduction: We report brigatinib long-term efficacy and safety from phase 1/2 and phase 2 (ALTA) trials in ALK–rearrangement positive (ALK+) NSCLC. Methods: The phase 1/2 study evaluated brigatinib 30 to 300 mg/d in patients with advanced maligna
Externí odkaz:
https://doaj.org/article/78d40f5a880944a8b24323de142222e5
Autor:
Andrew Elliott, Michelle Saul, Jia Zeng, John L. Marshall, Edward S. Kim, Misako Nagasaka, Heinz-Josef Lenz, Lee Schwartzberg, David Spetzler, Jim Abraham, Joanne Xiu, Phillip Stafford, W. Michael Korn
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract Patients with cancer demonstrate particularly poor outcomes from COVID-19. To provide information essential for understanding the biologic underpinnings of this association, we analyzed whole-transcriptome RNA expression data obtained from a
Externí odkaz:
https://doaj.org/article/de659d81a8a243fe8527f66b921f70ed
Autor:
James Chih-Hsin Yang, Martin Schuler, Sanjay Popat, Satoru Miura, Keunchil Park, Antonio Passaro, Filippo De Marinis, Flavio Solca, Angela Märten, Edward S. Kim
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionPreviously, we developed a database of 693 patients with NSCLC and uncommon EGFR mutations treated with afatinib. Here, we provide an update of >1000 patients, with more data on specific mutations.MethodsPatients were identified from a pr
Externí odkaz:
https://doaj.org/article/06285341cf024f7fb6cee27c5cc600a1
Autor:
Edward S. Kim, MD, Sigrid Balser, PhD, Klaus B. Rohr, PhD, Ragna Lohmann, PhD, Bernd Liedert, PhD, Dorothee Schliephake, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100248- (2022)
Introduction: Biological therapies such as bevacizumab have improved survival in patients with NSCLC. This study was conducted to confirm the equivalent efficacy of the biosimilar candidate BI 695502 to the bevacizumab reference product (RP). Methods
Externí odkaz:
https://doaj.org/article/8aa29ceaae964afeb78c42ab102398ac
Autor:
Sara I. Pai, Ezra E. W. Cohen, Derrick Lin, George Fountzilas, Edward S. Kim, Holger Mehlhorn, Neus Baste, Daniel Clayburgh, Loren Lipworth, Carlo Resteghini, Nawar Shara, Takashi Fujii, Jun Zhang, Michael Stokes, Huifen Wang, Philip Twumasi-Ankrah, Sophie Wildsmith, Asud Khaliq, Giovanni Melillo, Norah Shire
Publikováno v:
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-14 (2019)
Abstract Background Programmed cell death ligand-1 (PD-L1) expression on tumor cells (TCs) is associated with improved survival in patients with head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy, although its role as a prognost
Externí odkaz:
https://doaj.org/article/a6cc8d6715dd481d84183933b4c912f5
Ethics and Clinical Research: Improving Transparency and Informed Consent in Phase I Oncology Trials
Autor:
Paul H. Frankel, Susan Groshen, Jan H. Beumer, Laura Cleveland, Edward S. Kim, Judith E. Karp
Publikováno v:
Journal of Clinical Oncology. 41:2155-2158
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8233890130990e53b70b055f788e8b5a
https://doi.org/10.1200/jco.22.01736
https://doi.org/10.1200/jco.22.01736
Autor:
Megan H, Jagosky, Colin J, Anderson, James T, Symanowski, Nury M, Steuerwald, Carol J, Farhangfar, Emily A, Baldrige, Jennifer H, Benbow, Michael B, Livingston, Joshua C, Patt, Will A, Ahrens, Jeffrey S, Kneisl, Edward S, Kim
Publikováno v:
Cancer Medicine. 12:7029-7038
Patients with unresectable dedifferentiated liposarcoma (DDLPS) have poor overall outcomes. Few genomic alterations have been identified with limited therapeutic options.Patients treated at Levine Cancer Institute with DDLPS were identified. Next gen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::987f34a322de0cc7dffc986d5ebe7bf4
https://doi.org/10.1002/cam4.5502
https://doi.org/10.1002/cam4.5502
Autor:
Sai-Hong Ignatius, Ou, Makoto, Nishio, Myung-Ju, Ahn, Tony, Mok, Fabrice, Barlesi, Caicun, Zhou, Enriqueta, Felip, Filippo, de Marinis, Sang-We, Kim, Maurice, Pérol, Geoffrey, Liu, Maria Rita, Migliorino, Dong-Wan, Kim, Silvia, Novello, Alessandra, Bearz, Pilar, Garrido, Julien, Mazieres, Alessandro, Morabito, Huamao M, Lin, Hui, Yang, Huifeng, Niu, Pingkuan, Zhang, Edward S, Kim
Publikováno v:
Scientia
Circulating tumor DNA; Non–small cell lung cancer; Tumor biomarker ADN tumoral circulante; Cáncer de pulmón de células no pequeñas; Biomarcador tumoral ADN tumoral circulant; Càncer de pulmó de cèl·lules no petites; Biomarcador tumoral Intr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c7948bf1ff461e62f90cbe6656037f9
https://doi.org/10.1016/j.jtho.2022.08.018
https://doi.org/10.1016/j.jtho.2022.08.018